All In Biotech

Drug Trial Radar · NCT00003835

Combination Chemotherapy in Treating Patients With Stage III Colon Cancer

Phase III Intergroup Trial of Irinotecan (CPT-11) (NSC# 616348) Plus Fluorouracil/Leucovorin (5-FU/LV) Versus Fluorouracil/Leucovorin Alone After Curative Resection for Patients With Stage III Colon Cancer

Last checked: Nov 19, 2026Latest source record: Oct 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,260

Planned (sponsor's estimate)

Start

May 1999

Primary completion

Aug 2007

Sponsor

Sponsor type
NIH
Collaborators
SWOG Cancer Research Network; North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
First posted
Apr 27, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon cancer. Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without irinotecan in treating patients who have undergone surgery for stage III colon cancer.

Conditions

  • Adenocarcinoma of the Colon
  • Stage III Colon Cancer

Interventions

  • leucovorin calciumDrug

    Given IV

  • fluorouracilDrug

    Given IV

  • irinotecan hydrochlorideDrug

    Given IV

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to recurrenceTime frame: From time of resection until documented disease progression, assessed up to 6 years
  2. SurvivalTime frame: Up to 6 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer and Leukemia Group B

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.